crucial, it is not the only source of information on treatment progress. Decades of research on psychosocial interventions have highlighted the relevance of studying not only the outcome but also the processes by which change occurs within treatments (Lambert, 2013) and numerous treatment processes have been shown to predict outcome (Norcross & Lambert, in press ).
The assessment of treatment process may be particularly relevant in the context of longterm treatment for chronic mental health conditions, including substance use disorders (SUD) and serious mental illness (SMI). In contrast to estimated trajectories for mood and anxiety symptoms, which are expected to diminish over the course of therapy (Cuijpers, van Straten, Andersson, & van Oppen, 2008; Westen & Morrison, 2001) , symptoms for SUD and SMI may not follow this pattern (Hayes, Laurenceau, Feldman, Strauss, & Cardaciotto, 2007; Warner, 2009 ). Patterns of substance use have been shown to include sudden and discontinuous change that is better predicted by nonlinear than linear change models (e.g., catastrophe modeling based on dynamical systems theory; Witkiewitz & Marlatt, 2007) . Symptoms of SMIs with relatively modest full remission rates (e.g., schizophrenia; Warner, 2009) may likewise not be expected to diminish in a linear fashion over the course of treatment. Therefore, process variables may be more sensitive to the progress of therapy and factors that predict key outcomes for chronic mental illness, such as treatment retention.
Of the various psychotherapy processes that have been linked to treatment outcome (e.g., therapist empathy, patient emotional experiencing; Norcross & Lambert, in press), therapeutic alliance has been the most robust (Flückiger, Del Re, Wampold, & Horvath, 2018) . Therapeutic alliance has been defined as the personal bond between therapist and patient coupled with agreement on the tasks and goals of therapy (Horvath et al., 2011) . In a recent meta-analysis of k = 295 studies representing over 30,000 patients, alliance was moderately linked with treatment outcome (r = .28; Flückiger et al., 2018) , with effects largely consistent across various psychological treatments (e.g., cognitive behavioral therapy, psychodynamic psychotherapy) and alliance raters (i.e., patient-, observer-, or therapist-rated). Some variation in the strength of the alliance-outcome association was found across diagnoses, with effects smaller for samples with substance use disorders (r = .14) and when treatment drop-out was used as the outcome (Flückiger et al., 2018) . Alliance has been positively linked with treatment outcomes in group therapy contexts as well (e.g., Joyce, Piper, & Ogrodniczuk, 2007; Tasca, Compare, Zarbo, & Brugnera, 2016) . In the context of group treatment, alliance has been shown to correlate highly with other key therapeutic relationship factors including group cohesion (Johnson, Burlingame, Olsen, Davies, & Gleave, 2005) , which itself has been robustly linked with treatment outcome in meta-analysis (r = .26, k = 55 studies; Burlingame, McClendon, & Yang, 2018) .
Due to the link between alliance and outcome, some MBC systems 1 have begun incorporating assessment of alliance (e.g., Partners for Change Outcome Management System
[PCOMS], Miller, Hubble, Chow, & Seidel, 2015; Outcome Questionnaire -Analyst, Lambert, 2015) . However, to our knowledge, MBC efforts within the VA have thus far focused solely on the assessment of psychiatric symptoms (Oslin et al., 2006; Pomerantz, Kearney, Wray, Post, & McCarthy, 2014) .
In addition to assessing alliance, MBC systems may be helpful in providing clinicians with a "signal" of difficulties in alliance formation. The use of symptom-focused treatment signals has been widely implemented in the MBC literature, and it appears that providing 1 An MBC system can be defined as one or more measures (e.g., symptom measures) paired with software capable of comparing patients' trajectories of change with normative data for patient progress (Wampold, 2015) . Typically, measures are completed at each clinical encounter and the MBC system may or may not provide additional computer-generated feedback (e.g., indication of suicide risk, recommendations for ways to modify treatment, suggestions for additional dimensions to assess).
clinicians with a signal that treatment is not progressing as expected is part of what MBC effective (Delgadillo et al., 2018; Lambert, Hansen, & Finch, 2001; Lambert, 2015) . The pattern of scores that might constitute a signal of treatment difficulties in the domain of alliance remains less clear. Meta-analytic evidence suggests that alliance assessed at various points in treatment (e.g., early, middle, late) is associated with therapy outcome (Flückiger et al., 2018) . Further, it appears that aggregating alliance scores across multiple assessment points provides a more dependable metric of alliance than single assessments within outpatient psychotherapy for depression (Crits-Christoph, Connolly Gibbons, Hamilton, Ring-Kurtz, & Gallop, 2011) . Thus, an aggregated alliance rating may provide a global signal of the alliance strength over a course of treatment.
Another potential summary of alliance that may be a relevant signal in the context of MBC is the maximum alliance score. In contrast to aggregated scores, maximum alliance ratings indicate whether or not an individual ever reported high levels of alliance. Given a known negative skew to ratings of alliance (Tryon, Blackwell, & Hammel, 2008) and evidence that alliance fluctuates over the course of treatment (Stiles et al., 2004) , a patient's failure to ever provide high alliance ratings could also serve as a signal of difficulties in alliance formation.
Maximum alliance scores could therefore be used as a method for detecting individuals who have been consistently dissatisfied with their treatment (i.e., always providing lower ratings of alliance) and therefore at risk for drop-out.
Present Evaluation
This evaluation of a quality improvement project involved the implementation of ongoing, brief alliance-focused assessment within the context of a VA SUD clinic predominantly serving veterans with SMI. As treatment engagement is an ongoing concern within the veteran population (Hoge et al., 2014) , as well as among individuals with SMI receiving SUD treatment (Brown, Bennett, Li, & Bellack, 2011; Drake, Mueser, Brunette, & McHugo, 2004) , we were interested in whether alliance ratings could be used to predict treatment engagement. Veterans attending SUD groups provided ratings of alliance that were reviewed by group leaders and used to inform treatment (e.g., initiate a discussion with individual group members or the group as a whole regarding aspects of treatment). We examined both average and maximum alliance ratings as predictors of treatment engagement, given that each provide potentially unique information about the strength of the therapeutic relationship.
Our evaluation addressed two empirical hypotheses. First, based on the recommendation to the participating clinicians that they modify their interventions based on alliance feedback, we hypothesized that ratings of alliance would increase over the course of treatment. Second, we hypothesized that alliance ratings would demonstrate clinical utility through predicting treatment engagement. Specifically, we predicted that higher alliance would be associated with greater attendance at SUD groups that implemented the alliance measure as well as at SUD visits in general. We expected that both average and maximum alliance ratings would be associated with attendance.
Method Patients
Our sample included n = 98 veterans receiving SUD treatment within a VA hospital located in a large, metropolitan city. The XXXXX [omitted for blind review] VA is a Level 1 facility -the complexity category of VA facilities with the highest patient volume, level of patient risk, and degree of teaching and research activity. The SUD clinic is one of the largest substance use treatment programs in the VA system nationally. Patients were seen in one of n = 9 SUD groups engaging in alliance-focused MBC.
Sample demographics are reported in Table 1 . The average age within the sample was 55.72 years (SD = 10.66) and the vast majority of patients were male (n = 97, 99.0%) due in part to the availability of women-only SUD programming at the facility. The sample was majority White (n = 57, 58.2%), followed by Black (n = 31, 31.6%) and other race (n = 10, 10.2% 
Intervention
All patients were enrolled in SUD treatment that included a combination of weekly group sessions and periodic individual sessions. Group and individual treatment was based on relapse prevention and harm reduction principles and included elements of cognitive-behavioral therapy, Acceptance and Commitment Therapy, and mindfulness. Patients also received pharmacotherapy from medical providers located in the clinic. The nine treatment groups included in the current project were run by four VA providers (two psychologists, two social workers). Treatment groups were open (i.e., new patients were added to the group on an ongoing basis).
Patients provided alliance ratings at the end of each group meeting on paper forms distributed to the group. Instructions were given to group members to provide their honest responses. Patients were informed that group leaders were interested in learning about their experience in the group and would be reviewing their responses.
Group leaders reviewed all patient responses at the end of each group. Group leaders were encouraged to use their clinical judgment to determine when responses indicated concerns regarding a patient's alliance, in which case this feedback was discussed individually by the group leader with the patient. For example, when a patient indicated concerns regarding the groups "goals and topics," group leaders discussed the patient's understanding of the purpose of the group and the topics that the patient would like to discuss that were not currently being addressed. Group leaders' interventions in response to low alliance scores were not constrained by a particular treatment approach. However, group leaders tended to use motivational interviewing and cognitive-behavioral therapy (e.g., problem-solving) approaches in response to low ratings. Given most ratings were quite high, group leaders tended to discuss feedback that did not follow this pattern (e.g., ratings of 8 or lower).
Measures
Demographic and clinical characteristics. Patients' alliance ratings were linked with demographic and clinical characteristics drawn from their electronic medical record and clinic intake assessments. Data extracted included patients' age, race/ethnicity, Operation Enduring Freedom (OEF) or Operation Iraqi Freedom (OIF) service, legal involvement (probation or parole), and substance use and mental health diagnoses in the year prior to the initial alliance rating.
Treatment engagement. Treatment engagement was assessed through the electronic medical record and represented as a continuous variable. Engagement was operationalized in two ways: 1) the number of group sessions attended for the group in which alliance was being monitored (ascertained via SUD-related clinic stop code and clinic name), 2) the total number of SUD visit days attended (ascertained via SUD-related clinic stop code). In order to allow comparison of attendance rates across all patients, attendance was tracked for a period of three months prior to and following the initial alliance assessment. The three-month observation period was used regardless of whether or not an individual remained engaged in treatment during that time.
Group Session Rating Scale (GSRS; Duncan & Miller, 2007) . Alliance was assessed using the GSRS. The GSRS is a four-item measure designed to measure alliance in the context of group psychotherapy. The GSRS items reflect the theory of alliance in psychotherapy groups, which includes elements of both group cohesion and climate (Burlingame, McClendon, & Alonso, 2011) . Respondents provide ratings on a visual analog scale for the following areas:
Relationship, Goals and Topics, Approach or Method, and Overall. Descriptive anchors are provided for high and low alliance ratings for each item (e.g., the low Relationship anchor is "I did not feel understood, respected, and/or accepted by the leader and/or the group," the high Approach or Method anchor is "The leader and group's approach is a good fit for me"). The GSRS has been previously used in SUD groups and has shown desirable psychometric properties including: adequate internal consistency and test-retest reliability; correlation with measures of working alliance, group cohesion, and group climate; and prediction of early treatment change (Quirk, Miller, Duncan, & Owen, 2012) . Visual analog responses were measured using a ruler and converted to a 0 to 10-point scale. As recommended previously, the four items were summed to create a total GSRS alliance score (Quirk et al., 2012) which were used in all analyses. The four items showed high internal consistency reliability in the current sample ( = .92).
Alliance summary scores for models using alliance as a predictor of treatment engagement were computed in two ways. Alliance was calculated as either the aggregate (i.e., average) of all alliance assessments provided by an individual (Average Alliance) or as the maximum of all alliance ratings provided by an individual (Maximum Alliance) over the three months following the initial alliance rating. For example, if an individual provided the following alliance scores (7, 9, 8, 6 ) over the 3 months of group participation, the Average Alliance score would be 7.5 and the Maximum Alliance score would be 9.
Although related, these two metrics of alliance provide theoretically distinct information.
Average Alliance was intended to provide the most dependable global estimates of an individuals' alliance with the group and group leader, based on prior research indicating that dependability increased with aggregation across multiple observations (Crits-Christoph, Connolly Gibbons, Hamilton, Ring-Kurtz, & Gallop, 2011). In contrast, Maximum Alliance assesses whether or not an individual ever reported high levels of alliance. As low alliance ratings were being discussed with group members and we hypothesized that alliance ratings would therefore increase over time, persistently low ratings may serve as a "signal" of difficulties in the alliance.
Data Analysis
Separate multilevel models (Snijders & Bosker, 2012) were used to test our two hypotheses. To examine changes in GSRS total scores over time, we fit longitudinal multilevel models with GSRS observations nested (Level 1) within 98 patients over time (Level 2).
Subsequent models examined the impact of nesting of patients within nine treatment groups (Level 3) and four providers (Level 4) using 2 log-likelihood tests. Demographic covariates (race/ethnicity, OEF/OIF veteran status, age, drug use diagnosis, legal involvement) were also included. The equation for the simpler two-level models was:
where Yij is the GSRS score for patient (j) at observation number (i). GSRS scores were predicted by a fixed intercept (00) and slope (01) that were equivalent across all individuals and a random intercept (u0j) that could vary across individuals, and an error term (eij). A subsequent model assessed changes in model fit with the addition of a random slope coefficient for observation number.
Next, multilevel models were constructed predicting treatment engagement (i.e., attendance) from either Average Alliance or Maximum Alliance. Again, demographic covariates were also included. Three-level models were tested accounting for nesting of patients within treatment groups and providers:
where Yijk is the number of sessions attended by patient (i) in treatment group (j) led by provider (k). Attendance was predicted by a fixed intercept (000) and slope (1jk) that were equivalent across all individuals and random intercepts that could vary across groups (v00k) and providers (u0jk), and an error term (eijk).
Sensitivity analyses were run with GSRS or attendance outliers excluded. Outliers were defined as values three or more standard deviations from the mean.
In order to increase ease of interpretation of our results, we included Cohen's (1988) f 2 , a standardized effect size that has been recommended for use in the context of multilevel models (Selya et al., 2012) . Like more commonly used effect sizes (e.g., Cohen's [1988] 
includes guidelines for interpretation of the magnitude of effects (i.e., small, medium, large).
Results
Patients had an average of 10.85 (SD = 7.07) SUD visit days and attended 6.37 (SD = 3.89) visits of the group where MBC was being implemented (see Supplemental Materials Tables 1 and 2 for the distribution of attendance pre-and post-initial GSRS administration).
Patients completed a total of 498 GSRS ratings. GSRS scores were generally high with an overall mean of 8.96 (SD = 1.36). The sample mean Average Alliance was 8.82 (SD = 1.24) and the sample mean Maximum Alliance was 9.35 (SD = 1.06). A large and statistically significant correlation was observed between these two metrics of alliance (r = .85, p < .001).
Several outliers (≥ 3 standard deviations from the mean) were identified in the data set including 13 low outlier individual GSRS ratings (out of n = 498 total ratings), two low outlier Average Alliance scores (out of n = 98 patients), three low outlier Maximum Alliance scores (out of n = 98 patients), and one high outlier SUD visits attendance value (out of n = 98 patients). As described below, sensitivity analyses were conducted with these values excluded.
Changes in Alliance Over Time
An initial longitudinal multilevel model including only a fixed slope for observation number and a patient-level random intercept showed a significant increase in GSRS scores over Table 2 . Based on an f 2 effect size value of 0.033, this model shows a small magnitude increase in GSRS scores over time. Increases in GSRS scores over time remained significant in a sensitivity analysis that excluded low outlier GSRS values (B = 0.077, p < .001).
Alliance Predicting Treatment Engagement
Three-level models examined whether alliance ratings were associated with treatment engagement. In models with no additional predictors, Average Alliance was not associated with attendance at either SUD visits in general (B = 0.76, p = .175) or MBC group visits (B = 0.39, p = .212). Results were unchanged when modeling demographic covariates and when excluding either low Average Alliance outliers or the high SUD visit attendance outlier (Table 3) .
Associated standardized effect sizes were also very small (f 2 s = 0.021 and 0.009, for SUD visits in general and MBC group visits, respectively).
In contrast, higher Maximum Alliance scores were associated with greater attendance for both SUD visits in general (B = 1.86, p = .003) and MBC group visits (B = 1.06, p = .003).
Results were unchanged when modeling demographic covariates as well as when excluding low Maximum Alliance outliers and the high SUD visits attendance outlier (Table 3) . Associated standardized effect sizes were in the small range (i.e., 0.02 ≤ f 2 ≤ 0.15, Cohen [1992] ; f 2 s = 0.088 and 0.079, for SUD visits in general and MBC group visits, respectively).
Discussion
MBC has been identified as a priority treatment innovation for improving mental health outcomes with the VA system (Oslin et al., 2006; Pomerantz et al., 2014) . The current evaluation examined the clinical utility of routinely monitoring therapeutic alliance in SUD groups for veterans, predominantly those with comorbid SUD and SMI. At the most basic level, our results suggest that alliance-focused MBC is feasible within a VA SUD clinic, notably within a predominantly SMI context where patients frequently present with significant psychiatric and/or cognitive impairments. Patients and providers appeared willing and able to complete a very brief (four item) measure of alliance at the end of each group meeting. Indeed, with MBC presented by clinical staff as a routine part of care, no patients were reported refusing to complete the GSRS measure at the conclusion of group meetings. This is consistent with a previous study showing the feasibility of routine alliance assessment in the context of SUD treatment (Forman et al., 2007) . Our results also indicated that patient-rated alliance scores increased over the course of time, with a small magnitude increase with each additional session attended (f 2 = 0.033). This was anticipated, as group leaders were explicitly encouraged to discuss alliance ratings with group members, in particular when ratings were low and may therefore indicate difficulties in alliance formation.
Most importantly, it appeared that patient-rated alliance was prognostic of treatment engagement. Interestingly, this was the case only for the maximum alliance rating, and not for the average rating of alliance. Patients whose highest alliance rating was low (e.g., due to dropping out of treatment prior to showing the sample's typical increase over time, failing to ever show the high levels of alliance reported by the modal patient) attended the fewest SUD visits and MBC group visits over the three-month observation period. Based on standardized effect sizes, this relationship was in the small range (f 2 s = 0.088 and 0.079, for SUD visits in general and MBC group visits, respectively), supporting the validity of maximum alliance as a predictor of treatment engagement. This finding specifically suggests that maximum alliance scores may be a valuable signal of difficulties in the alliance. This possibility is consistent with a recent multisite, randomized controlled trial showing the MBC was more effective than treatment-as-usual only for individuals who were not on track for symptom improvement (Delgadillo et al., 2018) . It has long been recognized that alliance scores change over the course of psychotherapy (Stiles et al., 2004) , and it may be that individuals who never report high ratings of alliance are particularly at risk for treatment drop-out. This possibility should be examined further in larger datasets and those collected in other treatment contexts (e.g., non-SUD treatment, treatments with explicit start and end points).
The lack of relationship between average patient-rated alliance scores and treatment engagement is consistent with the relatively weaker association between alliance and treatment drop-out in general and between alliance and treatment outcome generally in SUD treatment (Flückiger et al., 2018) . Of note, the effect for average alliance was in the expected direction, although not statistically significant in our sample of 98 and of small magnitude (f 2 s = 0.021 and 0.009, for SUD visits in general and MBC group visits, respectively). It is possible that a significant relationship would be observed if examined in a larger sample with greater power to detect small effects. In contrast to maximum alliance ratings, which may function as a signal for alliance difficulties, average alliance ratings may provide a more reliable yet diffuse assessment of alliance that obscures difficulties in alliance formation. Of course, while the two metrics are correlated in the current sample (r = .85) and would be mathematically equivalent for individuals who report the same score at all assessments, maximum alliance may be more sensitive in the current context.
Our evaluation project, although with numerous limitations (discussed below), may have implications for psychologists in public sector settings serving in various clinical, administrative, and research capacities. Those in clinical roles could consider collecting a brief assessment of alliance as a method for detecting risk for treatment drop-out. Based on our findings, clinicians would be encouraged to attend to instances in which low alliance ratings are consistently provided, potentially signaling disruption in the therapeutic relationship. Even in the absence of formal quantitative alliance assessment, clinicians can attend to qualitative indications of low alliance (i.e., low agreement on the tasks and goals of therapy, lack of an emotional bond) and attempt to improve these elements of treatment (e.g., through alliance repair; Eubanks, Muran, & Safran, 2018) . Administrators may be encouraged by the relative ease of including alliancefocused MBC within treatment, along with initial evidence that this measure includes clinically meaningful information. In tandem with other large-scale MBC efforts, some of which have included brief alliance assessment (e.g., Group Health; Steinfeld et al., 2016) , the current evaluation adds to a growing body of literature supporting the feasibility and utility of MBC.
These findings may be helpful for increasing stakeholder buy-in, particularly among providers who may be skeptical of MBC (Boswell, Kraus, Miller, & Lambert, 2015; Dowrick et al., 2009) .
Based on the current study, alliance may be a candidate construct to include along with symptom measures within existing MBC implementation efforts (Pomerantz et al., 2014) . Lastly, for public sector researchers, the current evaluation study may serve as an example of ways in which clinical data generated as a routine part of MBC may be useful to address open research questions. As MBC is implemented at scale, the massive amounts of treatment outcome and process data generated could be used to identify actionable predictors of treatment effectiveness (e.g., clinic-level variables; Clark et al., 2018) as targets for health service innovations.
Future studies could expand on this work. An ideal study would include both a control condition and randomization of patients to alliance MBC and control (e.g., treatment-as-usual)
conditions in order to evaluate whether the inclusion of alliance assessment impacts treatment outcomes and engagement. Such a study design would follow numerous other studies conducted on symptom-focused MBC (see Delgadillo et al., 2018; Knaup et al., 2009; Shimokawa et al., 2010) , including work examining MBC in military samples with SUD (Schuman, Slone, Reese, & Duncan, 2015) . It may be that being able to associate alliance ratings to a specific patient (as was done in the current evaluation) is important for responding to feedback and may explain a lack of outcome improvement associated with anonymous ratings of alliance in the context of SUD treatment (Crits-Christoph et al., 2010) . It would also be valuable to see whether routinely monitored alliance predicts treatment engagement in non-SUD treatment contexts, especially those with high risk for treatment drop-out (e.g., post-traumatic stress disorder outpatient clinics within the VA; Imel, Laska, Jakupcak, & Simpson, 2013; Seal et al., 2010) . Another avenue to explore is the possibility of assessing alliance ratings outside of a clinical encounter. A growing body of literature documents the use and potential clinical relevance of remote MBC for mental health treatment (Goldberg et al., 2018) , and increased sophistication and ubiquity of mobile technologies may make these methodologies increasingly feasible. Assessing alliance outside of the context of a clinical encounter could alert providers to patients who are at risk for treatment drop-out due to alliance-related concerns.
Future studies could also continue to investigate areas of active debate within the alliance-outcome literature, such as questions of potential patient-level factors that might explain the alliance-outcome relationship (e.g., high problem severity, unstable emotional states; Flückiger et al., 2018) . The current evaluation examined some patient-level variables that may theoretically be linked to both ratings of alliance and attendance (e.g., legal involvement, drug use disorders), and found the relationship between maximum alliance and attendance to be robust to these factors. However, future studies could examine more proximal patient-level factors that could explain variance in alliance as a relational variable (e.g., attachment style; Diener, & Monroe, 2011) .
The current evaluation has several limitations. First, patients were included at varying points in their treatment. Meta-analytic evidence suggests that the timing of alliance assessment impacts the strength of the alliance-outcome association, with a weaker relationship between early alliance and outcome (Flückiger et al., 2018) . Substantively, the meaning of alliance may have legal involvement but not be mandated to attend). A future study could examine whether relationships between alliance and engagement differ for those with and without mandated treatment. A sixth limitation was a negative skew in our alliance variable. Although expected (Tryon et al., 2008) , this may have attenuated the relationship between alliance and engagement (Cohen, Cohen, West, & Aiken, 2003 6.37 3.89 1 14 Note: GSRS = Group Session Rating Scale; SUD visit days = all substance use disorder-related visit codes from medical record in three months prior to initial GSRS rating (i.e., baseline) or following initial GSRS rating (i.e., index); MBC (measurement-based care) group visits = all visits to group where GSRS was assessed in three months prior to initial GSRS rating (i.e., baseline) or following initial GSRS rating (i.e., index). Possible range of all alliance scores (GSRS Total, Average Alliance, Maximum Alliance) was from 0 to 10. 
